复发难治性多发性骨髓瘤的免疫靶向治疗及存在的问题

国际肿瘤学杂志››2021,Vol. 48››Issue (6): 381-384.doi:10.3760/cma.j.cn371439-20200622-00074

• 综述 •上一篇

复发难治性多发性骨髓瘤的免疫靶向治疗及存在的问题

孙睿婕¹, 单宁宁^1,²()

¹山东大学附属省立医院山东省立医院血液内科,济南 250021
²betway必威登陆网址附属省立医院山东省立医院血液内科,济南 250021

收稿日期:2020-06-22修回日期:2020-07-22出版日期:2021-06-08发布日期:2021-06-24
通讯作者:单宁宁 E-mail:snning@126.com
基金资助:
济南市科技计划(201907021)

Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma

Sun Ruijie¹, Shan Ningning^1,²()

¹Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong Provincial Hospital, Jinan 250021, China
²Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong Provincial Hospital, Jinan 250021, China

Received:2020-06-22Revised:2020-07-22Online:2021-06-08Published:2021-06-24
Contact:Shan Ningning E-mail:snning@126.com
Supported by:
Science and Technology Plan of Jinan of China(201907021)

摘要/Abstract

摘要：

多发性骨髓瘤以及复发难治性多发性骨髓瘤的新型免疫靶向治疗药物主要包括免疫调节剂、蛋白酶体抑制剂、单克隆抗体、免疫检查点抑制剂、组蛋白去乙酰化酶及嵌合抗原受体。尽管自体造血干细胞移植及新药的应用改善了患者预后,但仍需更有效的治疗手段和策略应对治疗中出现的不良反应及复发情况。

关键词:多发性骨髓瘤,分子靶向治疗,免疫治疗

Abstract:

The new immune and targeted therapy medicines of multiple myeloma and recurrence of refractory multiple myeloma mainly include immunomodulatory drugs, proteasome inhibitors, monoclonal antibody, immune monitoring point inhibitors, histone deacetylase and chimeric antigen receptor. Although the emergence of new drugs and the application of autologous hematopoietic stem cell transplantation have significantly improved the prognosis of patients, more effective treatment methods and treatment strategies are still required to deal with the adverse reactions and the condition of recurrence during treatment.

Key words:Multiple myeloma,Molecular targeted therapy,Immunotherapy

孙睿婕, 单宁宁. 复发难治性多发性骨髓瘤的免疫靶向治疗及存在的问题[J]. 国际肿瘤学杂志, 2021, 48(6): 381-384.

Sun Ruijie, Shan Ningning. Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma[J]. Journal of International Oncology, 2021, 48(6): 381-384.

参考文献30

[1]	Schinke M, Ihorst G, Duyster J, et al. Risk of disease recurrence and survival in patients with multiple myeloma: a german study group analysis using a conditional survival approach with long-term follow-up of 815 patients[J]. Cancer, 2020,126(15):3504-3515. DOI: 10.1002/cancr.32978. doi:10.1002/cncr.v126.15
[2]	Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma[J]. Blood, 2020,136(24):2731-2740. DOI: 10.1182/blood.2020006540. doi:10.1182/blood.2020006540
[3]	Szalat R, Munshi NC. Novel agents in multiple myeloma[J]. Cancer J, 2019,25(1):45-53. DOI: 10.1097/PPO.0000000000000355. doi:10.1097/PPO.0000000000000355
[4]	Chim CS, Kumar SK, Orlowski RZ, et al. Correction: management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond[J]. Leukemia, 2019,33(4):1058-1059. DOI: 10.1038/s41375-019-0410-3. doi:10.1038/s41375-019-0410-3pmid:30842604
[5]	Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma Ⅸ results and meta-analysis[J]. Blood, 2012,119(1):7-15. DOI: 10.1182/blood-2011-06-357038. doi:10.1182/blood-2011-06-357038
[6]	Gormley NJ, Ko CW, Deisseroth A, et al. FDA drug approval: elotuzumab in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma[J]. Clin Cancer Res, 2017,23(22):6759-6763. DOI: 10.1158/1078-0432.CCR-16-2870. doi:10.1158/1078-0432.CCR-16-2870pmid:28249893
[7]	Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma[J]. Blood, 2016,128(4):497-503. DOI: 10.1182/blood-2016-02-700872. doi:10.1182/blood-2016-02-700872pmid:27226434
[8]	Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study[J]. Leuk Lymphoma, 2018,59(6):1364-1374. DOI: 10.1080/10428194.2017.1376743. doi:10.1080/10428194.2017.1376743
[9]	Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med, 2016,374(17):1621-1634. DOI: 10.1056/1516282. doi:10.1056/NEJMoa1516282
[10]	Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma[J]. Leuk Res, 2014,38(1):1-9. DOI: 10.1016/j.leukres.2013.10.018. doi:10.1016/j.leukres.2013.10.018
[11]	Badros A, Singh Z, Dhakal B, et al. Marizomib for central nervous system-multiple myeloma[J]. Br J Haematol, 2017,177(2):221-225. DOI: 10.1111/bjh.14498. doi:10.1111/bjh.2017.177.issue-2
[12]	Spencer A, Harrison S, Zonder J, et al. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results[J]. Br J Haematol, 2018,180(1):41-51. DOI: 10.1111/bjh.14987. doi:10.1111/bjh.2018.180.issue-1
[13]	Zhu H, Wang T, Xin Z, et al. An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro[J]. Acta Biochim Biophys Sin (Shanghai), 2019,51(10):1034-1040. DOI: 10.1093/abbs/gmz093. doi:10.1093/abbs/gmz093
[14]	Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects[J]. Leukemia, 2013,27(2):430-440. DOI: 10.1038/leu.2012.183. doi:10.1038/leu.2012.183pmid:22763387
[15]	Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma[J]. Blood, 2016,128(1):37-44. DOI: 10.1182/blood-2016-03-705210. doi:10.1182/blood-2016-03-705210pmid:27216216
[16]	Usmani SZ, Nahi H, Plesner T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials[J]. Lancet Haematol, 2020,7(6):e447-e455. DOI: 10.1016/S2352-3026(20)30081-8. doi:10.1016/S2352-3026(20)30081-8
[17]	Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study[J]. Blood Cancer J, 2020,10(9):91. DOI: 10.1038/s41408-020-00357-4. doi:10.1038/s41408-020-00357-4pmid:32887873
[18]	Zhang T, Wang S, Lin T, et al. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma[J]. Oncotarget, 2017,8(20):34001-34017. DOI: 10.18632/oncotarget.16987. doi:10.18632/oncotarget.v8i20
[19]	Jagannath S, Heffner LT Jr, Ailawadhi S, et al. Indatuximab ravtansine (bt062) monotherapy in patients with relapsed and/or refractory multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2019,19(6):372-380. DOI: 10.1016/j.clml.2019.02.006. doi:S2152-2650(18)31566-0pmid:30930134
[20]	Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma[J]. Blood, 2017,129(25):3294-3303. DOI: 10.1182/blood-2016-09-740787. doi:10.1182/blood-2016-09-740787
[21]	Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma[J]. Blood, 2017,130(10):1189-1197. DOI: 10.1182/blood-2017-03-775122. doi:10.1182/blood-2017-03-775122
[22]	Ma Y, Liu W, Zhang L, et al. Effects of histone deacetylase inhibitor panobinostat (lbh589) on bone marrow mononuclear cells of relapsed or refractory multiple myeloma patients and its mechanisms[J]. Med Sci Monit, 2017,23:5150-5157. DOI: 10.12659/msm.904232. doi:10.12659/MSM.904232
[23]	Wahaib K, Beggs AE, Campbell H, et al. Panobinostat: a histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma[J]. Am J Health Syst Pharm, 2016,73(7):441-450. DOI: 10.2146/ajhp150487. doi:10.2146/ajhp150487
[24]	Liu JD, Sun CY, Tang L, et al. Efficacy and safety of panobinostat in relapsed or/and refractory multiple myeloma: meta analyses of clinical trials and systematic review[J]. Sci Rep, 2016,6:27361. DOI: 10.1038/srep27361. doi:10.1038/srep27361
[25]	Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma[J]. Blood, 2016,128(13):1688-1700. DOI: 10.1182/blood-2016-04-711903.
[26]	Baumeister SH, Murad J, Werner L, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AMN/MDS and multiple myeloma[J]. Cancer Immunol Res, 2019,7(1):100-112. DOI: 10.1158/2326-6066.CIR-18-0307. doi:10.1158/2326-6066.CIR-18-0307pmid:30396908
[27]	Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma[J]. J Clin Invest, 2019,129(6):2210-2221. DOI: 10.1172/JCI126397. doi:10.1172/JCI126397
[28]	Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma[J]. Immunotherapy, 2015,7(11):1187-1199. DOI: 10.2217/imt.15.77. doi:10.2217/imt.15.77
[29]	Kim JR, Mathew SO, Mathew PA. Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells[J]. Immunobiology, 2016,221(1):31-39. DOI: 10.1016/j.imbio.2015.08.005. doi:10.1016/j.imbio.2015.08.005
[30]	Wong SW, Comenzo RL. CD38 monoclonal antibody therapies for multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2015,15(11):635-645. DOI: 10.1016/j.clml.2015.07.642. doi:10.1016/j.clml.2015.07.642